Crossmark

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

Crossref DOI link: https://doi.org/10.1038/s41598-025-90136-7

Published Online: 2025-03-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Willoughby, David

Bognar, Ernest

Stanbery, Laura

Nagel, Casey

Wallraven, Gladice

Pruthi, Aman

Bild, Nicholas

Stamper, Ericca

Rao, Donald

Walter, Adam

Nemunaitis, John
License Information

Text and Data Mining valid from 2025-03-13

Version of Record valid from 2025-03-13
More Information

Article History

Received: 28 September 2024

Accepted: 11 February 2025

First Online: 13 March 2025

Declarations

:

: EB, LS, GW, DR, AW and JN are employees of Gradalis, Inc. JN is a board member of Gradalis, Inc. CN and AP are employed by Frontage Labs. DW and ES are recent previous employees of Frontage Labs. NB does not have conflict of interest to disclose.

Document is current

Any future updates will be listed below